Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) shares were up 3% during mid-day trading on Thursday . The company traded as high as $27.82 and last traded at $27.41, with a volume of 366,494 shares trading hands. The stock had previously closed at $26.61.

A number of research analysts recently issued reports on ALDR shares. Credit Suisse Group AG reissued an “outperform” rating and set a $40.00 price target on shares of Alder BioPharmaceuticals in a research report on Tuesday, March 29th. Jefferies Group reissued a “buy” rating and set a $62.00 price target on shares of Alder BioPharmaceuticals in a research report on Tuesday, March 29th. Leerink Swann reissued an “outperform” rating on shares of Alder BioPharmaceuticals in a research report on Tuesday, March 29th. Brean Capital started coverage on shares of Alder BioPharmaceuticals in a research report on Wednesday, April 20th. They set a “buy” rating and a $45.00 price target for the company. Finally, Wells Fargo & Co. started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, April 21st. They set an “outperform” rating for the company. Six research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $47.40.

The firm’s 50 day moving average price is $26.88 and its 200-day moving average price is $25.22. The stock’s market capitalization is $1.35 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.04. During the same quarter last year, the company posted ($0.40) EPS. Equities research analysts predict that Alder BioPharmaceuticals Inc. will post ($3.25) earnings per share for the current year.

In other Alder BioPharmaceuticals news, insider Mark James Litton sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $30.05, for a total transaction of $751,250.00. Following the transaction, the insider now owns 79,847 shares in the company, valued at $2,399,402.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jeffrey T. L. Smith sold 16,090 shares of the business’s stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $30.20, for a total transaction of $485,918.00. Following the transaction, the vice president now owns 16,090 shares in the company, valued at approximately $485,918. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently bought and sold shares of ALDR. Pyrrho Capital Management LP boosted its position in Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 42,343 shares during the period. Wells Fargo & Company MN boosted its position in Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares during the period. Brown Advisory Inc. boosted its position in Alder BioPharmaceuticals by 118.8% in the fourth quarter. Brown Advisory Inc. now owns 379,579 shares of the biopharmaceutical company’s stock worth $12,538,000 after buying an additional 206,108 shares during the period. ProShare Advisors LLC boosted its position in Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 3,058 shares during the period. Finally, California Public Employees Retirement System boosted its position in Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares during the period.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.